Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q4 EPS of $0.02, Offers Poor FY12 Guidance
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $161.62 +2.10%
EPS Growth %: -5.5%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -5.5%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q4 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.08 million.
Neurocrine Biosciences, Inc. sees FY2012 EPS of $-0.21-$-0.14, versus the consensus of $0.02. Neurocrine Biosciences, Inc. sees FY2012 revenue of $40-$45 million, versus the consensus of $51.72 million. The Company expects to have a net cash burn from operations of approximately $40 to $45 million in 2012.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Neurocrine Biosciences, Inc. sees FY2012 EPS of $-0.21-$-0.14, versus the consensus of $0.02. Neurocrine Biosciences, Inc. sees FY2012 revenue of $40-$45 million, versus the consensus of $51.72 million. The Company expects to have a net cash burn from operations of approximately $40 to $45 million in 2012.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
- Ridgepost Capital acquires Stellus Capital Management for $4B AUM
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
